BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference
September 08, 2022 08:00 ET
|
BioPorto A/S
September 8, 2022 BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference COPENHAGEN, DENMARK and BOSTON, MA, USA, September 8, 2022, (GLOBE NEWSWIRE) -- BioPorto...
BioPorto Announces Interim Results for the First Six Months of 2022
August 17, 2022 02:23 ET
|
BioPorto A/S
August 17, 2022Announcement no. 13 BioPorto Announces Interim Results for the First Six Months of 2022 COPENHAGEN, DENMARK and BOSTON, MA, USA, August 17, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S...
BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call
August 08, 2022 11:05 ET
|
BioPorto A/S
August 8, 2022News release BioPorto A/S to Host Quarterly Earnings Webcast and Analyst Call COPENHAGEN, DENMARK and BOSTON, MA, USA, August 8, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S BioPorto...
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
June 28, 2022 14:59 ET
|
BioPorto A/S
June 28, 2022Announcement no. 12 BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S. COPENHAGEN, DENMARK and BOSTON, MA, USA, June...
Moderated webcast with BioPorto’s management
June 21, 2022 11:00 ET
|
BioPorto A/S
June 21, 2022News release Moderated webcast with BioPorto’s management COPENHAGEN, DENMARK and BOSTON, MA, USA, June 21, 2022, (GLOBE NEWSWIRE) -- BioPorto A/S (CPH:BIOPOR) (BioPorto) today...
BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director
June 20, 2022 02:15 ET
|
BioPorto A/S
June 20, 2022News release BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director ...
Strong Performance of The NGAL Test Drives Revenue Growth
May 11, 2022 02:59 ET
|
BioPorto A/S
May 11, 2022Announcement no. 11 Strong Performance of The NGAL Test Drives Revenue Growth Revenues totaled DKK 6.5 million in the first quarter of 2022, a 17% increase over the prior year. This...
Grant of warrants
May 05, 2022 14:17 ET
|
BioPorto A/S
May 5, 2022Announcement no. 10 Grant of warrants The Board of Directors of BioPorto A/S (“BioPorto”) (Nasdaq: BIOPOR), in accordance with its current authorization to issue warrants to key employees...
BioPorto A/S - Annual General Meeting
April 28, 2022 08:49 ET
|
BioPorto A/S
April 28, 2022Announcement no. 9 BioPorto A/S - Annual General Meeting Today, BioPorto A/S held its Annual General Meeting. The general meeting resolved to conduct the meeting in English without...
Notice Convening the Annual General Meeting
April 06, 2022 05:24 ET
|
BioPorto A/S
April 6, 2022 Announcement no. 8 NOTICE CONVENING THE ANNUAL GENERAL MEETING The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (the “Company”): April 28,...